Kerala Ayurveda share price & results
- Jun 2026
- Oct 2026
Kerala-based Ayurveda company making patented K-series herbal formulations and consumer wellness products, operating Ayurvedic clinics/wellness resorts and a US-based Ayurveda education academy.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 22.5 | +28.2% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -22.6 | +8.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -7.7 | −470.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
| Return on equity | −92.0 pts | Trailing twelve months | TTM to Jun 2026 | Not in the analysed materials. No older figure is substituted. | |
| Free cash flow margin | -22.61 | −16.0 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 11.74 | −12.7 pts | Trailing twelve months | TTM to Jun 2026 | Revenue change against the same period one year earlier. |
Price
Performance −65.9% 1Y
1Y: ₹425.1 on 24 Oct 2025 → ₹144.95. High ₹436.55 (30 Oct 2025), low ₹131.25 (23 Oct 2026).
- Previous close
- ₹139.25
- Market cap
- ₹268 Cr
- 52-week range
- ₹131.25 – ₹436.55
- One year
- −66.17%
Overview
- Symbol
- NSE:KERALAYUR
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Kerala Ayurveda Limited does
Based on the company's own presentations, annual report and earnings calls.
Kerala Ayurveda Limited manufactures and sells Ayurvedic herbal formulations and consumer wellness products, including its patented K-series range (K-10, K-10 Plus, K-13, K-13 Plus, K-1) targeted at blood-sugar control, inflammation/pain management and obesity, alongside products like Chyavanaprash, Swarnamukhi, Balakalpam and Myaxil. It runs Ayurvedic treatment/wellness facilities (including a hospital and the Ayurvedagram Heritage Wellness Centre) and a raw-drug processing unit in Kerala, and operates the Kerala Ayurveda Academy & Wellness Center in Milpitas, California, which offers Ayurvedic practitioner certifications, clinical internships and consultations. Through a joint venture with Sanghvi Brands Ltd, the company also develops and operates Ayurvedagram-branded wellness resorts and Ayurvedic spas within luxury hotels.
Segments
- Ayurvedic products & formulations
- Wellness centres, clinics & hospital
- US Academy & wellness center
- Ayurvedagram Wellness Resorts & Spas (JV with Sanghvi Brands)
- Manufacturing & operating units (Aluva/Kerala)
- 4 (Raw Drug Division-Kottai Nedumbaserry, Health Village-Aluva, KAL Hospital-Aluva, FG Depot-Panaikulam)
- Customers served (US distribution)
- 11,000+
- US Academy students & alumni
- 2,000+
- US Academy accredited content
- 6,000+ hours
- Land bank
- ~12.5 acres (8.5 acres at Manyali for Ayurvedagram Resort + 4 acres in Kerala for a new factory)
- JV partner (Sanghvi Brands) spa/wellness footprint
- 70+ locations globally (India, Middle East, Sri Lanka, USA)
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 6 fiscal years held (Mar 2021 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −471% (quarter to jun 2026 against jun 2025).
| Line item | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 19 | 19 | 19 | 18 | 21 | 22 | 25 | 23 |
| Expenses | 19 | 19 | 30 | 23 | 26 | 24 | 35 | 28 |
| Operating profit | -1 | 0 | -11 | -5 | -5 | -2 | -10 | -5 |
| Operating margin | −3.0% | 1.9% | −56.7% | −30.9% | −23.7% | −9.4% | −42.7% | −22.6% |
| Other income | 0 | 0 | 4 | 10 | 2 | 1 | 5 | 1 |
| Interest | 0 | 0 | 3 | 1 | 3 | 2 | 2 | 3 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -1 | -0 | -11 | 3 | -6 | -4 | -9 | -8 |
| Tax rate | −23.9% | −50.0% | 9.0% | 19.8% | −8.0% | −4.9% | −11.9% | −4.5% |
| Net profit | -1 | -0 | -12 | 2 | -5 | -3 | -8 | -8 |
| EPS (₹ per share) | -0.45 | -0.07 | -9.86 | 1.72 | -4.48 | -2.88 | -6.10 | -5.90 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 81 | 68 | 73 | 86 |
| Expenses | 80 | 64 | 85 | 109 |
| Operating profit | 2 | 3 | -13 | -23 |
| Other income | 3 | 3 | 5 | 18 |
| Interest | 5 | 5 | 4 | 7 |
| Depreciation | 1 | 2 | 2 | 4 |
| Profit before tax | -0 | -0 | -13 | -16 |
| Net profit | -0 | 0 | -14 | -15 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 11 | 11 | 12 | 12 | 12 | 13 |
| Reserves | 1 | 4 | 21 | 13 | -7 | 23 |
| Borrowings | 61 | 64 | 64 | 56 | 85 | 74 |
| Other liabilities | 19 | 21 | 20 | 38 | 45 | 30 |
| Total liabilities | 92 | 99 | 116 | 119 | 135 | 140 |
| Fixed assets | 28 | 30 | 28 | 31 | 49 | 34 |
| Capital work in progress | 2 | 0 | 0 | 1 | 9 | 1 |
| Investments | 11 | 11 | 9 | 9 | 0 | 9 |
| Other assets | 50 | 57 | 79 | 77 | 78 | 95 |
| Total assets | 92 | 99 | 116 | 119 | 135 | 140 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Cash from operations | -1 | 9 | 9 | -5 | 2 | -25 |
| Cash from investing | -2 | 1 | -5 | -1 | -6 | -3 |
| Cash from financing | 2 | -11 | -2 | 21 | -12 | 30 |
| Net cash flow | -1 | -1 | 2 | 15 | -16 | 2 |
| Free cash flow | -2 | 6 | 8 | -6 | -5 | -28 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 83 | 68 | 70 | 74 | 108 | 136 |
| Inventory days | 238 | 213 | 200 | 183 | 176 | 146 |
| Days payable | 126 | 122 | 124 | 115 | 90 | 134 |
| Cash conversion cycle | 195 | 159 | 146 | 142 | 194 | 148 |
| Working capital days | -26 | -157 | -37 | -202 | -53 | -33 |
| Return on capital employed | −1.0% | 10.0% | 6.0% | 6.0% | −11.0% | −9.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Ownership
Who owns it
Public hold 61.12% as of Oct 2026; institutions added 0.15 pts since Sept 2026.
- Promoters 38.70%
- Foreign institutions 0.15%
- Domestic institutions 0.03%
- Public 61.12%
Who bought this quarter
since Sep 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- +4.56 pp 9.41% held
The same filing shows 11 holders trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Oct 2026 filing
Every holder of Kerala Ayurveda Limited above SEBI's 1% disclosure line, and what changed since Sep 2026.
| Holder | Stake | Change |
|---|---|---|
| 29.28% | −1.47 pp | |
| 9.41% | +4.56 pp | |
| 3.06% | −0.16 pp | |
| 2.39% | −0.12 pp | |
| NBFC / DFI | 1.73% | −0.09 pp |
| 1.68% | −0.09 pp | |
| 1.65% | −0.08 pp | |
| 1.26% | −0.07 pp | |
| 1.25% | −0.07 pp | |
| 1.25% | −0.06 pp | |
| 1.23% | −0.06 pp | |
| 1.16% | −0.06 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Kerala Ayurveda Limited
Free account: one company. Everything above stays public.
Write why you follow Kerala Ayurveda Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
Learn to analyse Kerala Ayurveda Limited
Guides on how to read this kind of business and the numbers that matter.